SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Webb Carol

(Last) (First) (Middle)
C/O CITIUS PHARMACEUTICALS, INC.
11 COMMERCE DRIVE, 1ST FLOOR

(Street)
CRANFORD NJ 07016

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Citius Pharmaceuticals, Inc. [ CTXR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
03/04/2024
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/04/2024 M 12,071 A $0.015 12,071 D
Common Stock 03/04/2024 F 236 D $0.766 11,835 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Purchase Common Stock) $0.015 03/04/2024 M 12,071 03/17/2017 03/17/2024 Common Stock 12,071 $0 0 D
Stock Option (Right to Purchase Common Stock) $0.7 (1) 10/10/2033 Common Stock 75,000 75,000 D
Stock Option (Right to Purchase Common Stock) $1.25 (2) 10/04/2032 Common Stock 75,000 75,000 D
Stock Option (Right to Purchase Common Stock) $2.04 (3) 10/11/2031 Common Stock 75,000 75,000 D
Stock Option (Right to Purchase Common Stock) $2 (4) 07/22/2031 Common Stock 15,000 15,000 D
Stock Option (Right to Purchase Common Stock) $1.69 (5) 02/16/2031 Common Stock 25,000 25,000 D
Stock Option (Right to Purchase Common Stock) $1.01 (6) 10/06/2030 Common Stock 35,000 35,000 D
Stock Option (Right to Purchase Common Stock) $1.39 (7) 07/07/2030 Common Stock 25,000 25,000 D
Stock Option (Right to Purchase Common Stock) $0.67 (8) 10/08/2029 Common Stock 25,000 25,000 D
Stock Option (Right to Purchase Common Stock) $1.62 (9) 09/04/2028 Common Stock 15,000 15,000 D
Stock Option (Right to Purchase Common Stock) $3.45 (10) 09/13/2027 Common Stock 10,000 10,000 D
Stock Option (Right to Purchase Common Stock) $12 (11) 06/23/2026 Common Stock 13,334 13,334 D
Explanation of Responses:
1. The options were granted on October 10, 2023. The options will vest 100% on the one-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of the vesting date.
2. The options vested in full on October 4, 2023.
3. The options vested in full on October 11, 2022.
4. The options vested in full on July 22, 2022.
5. The options vested in full on February 16, 2022.
6. The options vested in full on October 6, 2021.
7. The options vested in full on July 7, 2021.
8. The options vested in full on October 8, 2020.
9. The options vested in full on September 4, 2019.
10. The options vested in full on September 13, 2018.
11. The options vested in full on June 23, 2017.
/s/ Alexander M. Donaldson, by power of attorney 08/30/2024
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Citius Pharmaceuticals (NASDAQ:CTXR)
Historical Stock Chart
Von Sep 2024 bis Okt 2024 Click Here for more Citius Pharmaceuticals Charts.
Citius Pharmaceuticals (NASDAQ:CTXR)
Historical Stock Chart
Von Okt 2023 bis Okt 2024 Click Here for more Citius Pharmaceuticals Charts.